Vantage Press & Media

New Vaccine Therapy Helps Sebastian Resident Beat Prostate Cancer - Cancer Care Centers of Brevard is one of the First in Brevard County to Offer Provenge® Treatment to Advanced Prostate Cancer Patients

MELBOURNE, Fla. (April 6, 2012) – Patients with advanced prostate cancer now have access to a viable new treatment alternative to chemotherapy at Cancer Care Centers of Brevard (CCCB), which is among the first sites in Brevard County to offer the innovative immunotherapy treatment – sipuleucel-T. In December 2011, Dr. Carl

Tahn, medical oncologist at CCCB in Rockledge successfully treated one of the first patients in Brevard County with sipuleucel-T. Sold under the brand name Provenge®, sipuleucel-T is the first in a new class of treatment known as autologous cellular immunotherapies.

Ken Seifert, 82, of Sebastian, FL recently completed his vaccine treatments in February 2012 and he is grateful for having access to Provenge. “After having undergone radiation treatment in 2002, my cancer had suddenly returned in the summer of 2011. Thankfully, this new treatment was available and prescribed by Dr. Tahn because it has dramatically improved my quality of life and hopefully helped me beat my cancer.”"What is exciting about this line of therapy is that it uses

the patient's own immune system to fight the cancer," says Dr. Tahn. “Advanced prostate cancer patients like Mr. Seifert are seeing incredible results from this treatment, and we are very encouraged about Provenge’s future.”Provenge is derived from the patient's own immune cells, or autologous cells, with each dose

unique to that patient, and the therapy is designed to stimulate a patient's immune system to identify and target prostate cancer cells. The new drug, made by Dendreon Corp. in Seattle, WA., was approved by the U.S. Food and Drug Administration in April 2010 for the treatment of men with asymptomatic or minimally symptomatic metastatic castrate resistant (hormone refractory) prostate cancer.

The American Cancer Society estimates that in 2012, 241,740 men will be diagnosed with prostate cancer and 28,170 will lose their lives to it. Prostate cancer is the second leading cause of cancer death in American men, behind only lung cancer. Prostate cancer can be a serious disease, but most men diagnosed with prostate cancer do not die from it. In fact, more than 2.5 million men in the United States who have been diagnosed with prostate cancer at some point are still alive today.

Typically, patients with advanced prostate cancer are treated with surgery or chemotherapy, both of which can have significant side effects, including incontinence and loss of sexual function. In clinical trials, the most common adverse events (incidence ≥15 percent) reported for Provenge included chills, fatigue, fever, back pain, nausea, joint ache, and headache. A patient receives three courses of treatment, each given about two weeks apart, for over about a month. A patient will usually have blood cells drawn early in the week to create the Provenge vaccine, which is then reinfused into the patient late in the week.

“Provenge provides patients a safe and effective clinical treatment option to chemotherapy,” explained Dr. Tahn. “We believe this treatment may redefine how we fight prostate cancer for years to come.”

For information about Provenge and the Cancer Care Centers of Brevard, please call (321) 636-2111, in Sebastian at (772) 589-1995, or visit
www.cancercarebrevard.com.      

CONTACT:
Trace Longo
Longo Communications
(949) 364-2821

Carolyn Hall
Operations Manager
Cancer Care Centers of Brevard
(321) 722-1342